ACR Meeting Abstracts

ACR Meeting Abstracts

Abstract Number: 1279

Impact of Active Lupus Nephritis in Patient-Reported Outcomes from a Latin American, Multicenter Lupus Cohort

Romina Nieto1, Eduardo Ferreira Borba2, Eugenia Settecasse3, Diana Fernandez-Avila4, Laura Maurelli5, Carla Gobbi6, Verónica Saurit7, Fernando Arizpe8, Julieta Daniele9, Maria Constanza Bertolaccini10, Eduardo Kerzberg11, María de los Ángeles Gargiulo12, Anabella Rodriguez13, Ana Carolina Londe14, Vitalina Sousa Barbosa15, Andrese Aline Gasparin16, Carolina Albanez A Cunha Andrade17, Luciana Parente Costa Seguro18, Lucas Victoria de Oliveira Martins19, Oscar Neira20, Carolina Llanos21, Loreto Massardo22, Antonio Iglesias23, Ivana Nieto Aristizábal24, Gloria Vasquez25, Paul Mendez-Patarroyo26, Lizeth de la Hoz Rueda23, José Martínez Pérez27, Reyna Sánchez Briones28, Mario Pérez Cristóbal29, Eduardo Martin-Nares30, Yaneli Juárez-Vicuña31, Yelitza Gonzalez Bello32, Jorge González García33, Dionicio Galarza-Delgado34, Marcos Vázquez35, Patricia Langjarh35, Magaly Alva Linares36, Cristina Reategui-Sokolova37, Armando Calvo Quirós38, Edral Rodriguez39, Ricardo Robaina40, Martín Rebella41, Graciela Alarcn42, Ashley Orillion43, Chetan Karyekar44, Federico Zazzetti45 and Guillermo Pons-Estel46, 1Hospital Provincial de Rosario, Rosario, Argentina, 2Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brazil, 3Instituto de Investigaciones Teóricas y Aplicadas. Facultad de Ciencias Económicas y Estadistica. Universidad Nacional de Rosario, Rosario, Argentina, 4Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 5Hospital Italiano de Córdoba, Córdoba, Argentina, 6Hospital Córdoba, Córdoba, Argentina, 7Hospital Privado Universitario de Córdoba, Córdoba, 8Hospital HIGA San Martín, La Plata, Argentina, 9Sanatorio Británico, Rosario, Argentina, 10Hospital Padilla, San Miguel de Tucumán, Argentina, 11Hospital General de Agudos J.M. Ramos Mejía, Buenos Aires, Argentina, 12Instituto de Investigaciones Médicas Alfredo Lanari, Buenos Aires, Argentina, 13CEMIC, Buenos Aires, Argentina, 14Universidade Estadual de Campinas, Faculdade de Ciencias Médicas, São Paulo, Brazil, 15Hospital das Clinicas, Univerisad Federal de Goias, Goias, Brazil, 16Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil, 17Universidad Federal de Pernambuco, Recife, Brazil, 18Hospital Das Clinicas da Faculdade de Medicina da USP, São Paulo, Brazil, 19Universidad Federal São Paulo, São Paulo, Brazil, 20Hospital del Salvador, Santiago, Chile, 21Facultad de Medicina, Pontificia Universidad Catolica de Chile, Santiago, Chile, 22Universidad San Sebastián, Santiago, Chile, 23Clínica de la Costa Ltda., Barranquilla, Colombia, 24Fundación Valle del Lili, Cali, Colombia, 25Division of rheumatology, Universidad de Antioquia, Medellin, Colombia, 26Reumavance Group, Rheumatology section, Department of Internal Medicine, Fundación Santa Fe de Bogotá University Hospital; Department of Internal Medicine, School of Medicine, Universidad de Los Andes, Bogota, Colombia, 27Hospital Luis Vernaza, Guayaquil, Ecuador, 28Centro Médico La Raza, Ciudad de México, Mexico, 29Centro Médico Nacional Siglo XXI, Ciudad de México, Mexico, 30Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 31Instituto Nacional de Cardiología Ignacio Chávez, Ciudad de México, Mexico, 32Centro de Estudios de investigación Básica y Clínica S.C, Guadalajara, Mexico, 33Hospital Central Dr. Ignacio Morones Prieto, San Luís Potosí, Mexico, 34Hospital Universitario "Dr Jose E. Gonzalez", Monterrey, Mexico, 35Hospital de Clínicas I, Asunción, Paraguay, 36Hospital Nacional Edgardo Rebagliatti Martins, Lima, Peru, 37Hospital Guillermo Almenara Irigoyen, Lima, Peru, 38Hospital Cayetano Heredia, Lima, Peru, 39Hospital Docente Padre Billini, Santo Domingo, Dominican Republic, 40Clínica Médica C, Hospital de Clínicas, UDELAR, Montevideo, Uruguay, 41Unidad de Enfermedades Autoinmunes Sistémicas de Médica Uruguay Corporación de Asistencia Médica (MUCAM); Unidad de Enfermedades Autoinmunes Sistémicas del Hospital de Clínicas, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay, 42University of Alabama at Birmingham, Birmingham, AL, 43Global Commercial Strategic Organisation, Johnson and Johnson, Horsham, PA, 44Janssen R&D, Spring House, PA, 45Medical Affairs, Jan-Cil Argentina, Buenos Aires, Argentina, 46Grupo Oroño. Centro Regional de Enfermedades Autoinmunes y Reumaticas (GO-CREAR), Rosario, Argentina

Meeting: ACR Convergence 2021

Keywords: , , ,

Session Information

Date: Monday, November 8, 2021

Title: SLE – Diagnosis, Manifestations, & Outcomes Poster III: Outcomes (1257–1303)

Session Type: Poster Session C

Session Time: 8:30AM-10:30AM

Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by multiple and heterogeneous clinical manifestations that may negatively affect these patients’ quality of life (QoL) and their levels of activity and productivity, despite overall progress in treatment of the disease. The aim of this study is to assess lupus quality of life (LupusQol) and work productivity and activity impairment (WPAI) of daily life in a SLE multicenter Latin American cohort (GLADEL 2.0, Grupo Latino Americano De Estudio del Lupus) among patients with active lupus nephritis (LN) versus those without LN (never) and/or currently inactive LN.

Methods: The GLADEL 2.0 cohort enrolled SLE patients >18 years of age, from three different subsets: Group I: SLE patients, without renal involvement (never); Group II: SLE patients with prevalent renal involvement (at any time during their disease course), currently inactive; Group III: SLE patients with prevalent or incident renal involvement, currently active. Disease activity was ascertained with the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI-2k) and the Physician Global Assessment (PGA) and damage with the SLICC/ACR Damage Index (SDI). The differences in the baseline Lupus QoL (questions were categorized as never or present at different degree) and WPAI-Lupus [Questions 1 (Currently employed), 5 (Degree health affected productivity while working) and 6 (Degree health affected regular activities)] were analyzed among these three groups. We particularly were interested in examining in more detail Question 6 of the WPAI, that focus on activities of daily living and which is answered by everybody regardless of whether they are working or not. Numeric variables are reported as medians (interquartile ranges IQR) and compared using Wilcoxon test; categorical variables are reported as frequencies (percentages) and compared using Chi-square or Fisher test, as appropriate. To evaluate the impact of active versus inactive LN in WPAI (Question 6), a multivariate analysis (MV) was adjusted for possible confounders such as: sex, age, socioeconomic level, ethnicity, education, activity and damage in a negative binomial model.

Results: A total of 849 patients with a diagnosis of SLE were included; 344 in Group I, 205 in Group II and 300 in Group III. Their main sociodemographic and clinical features are shown in Table 1. Patients with active LN (group III) had a higher proportion of male patients, were younger at diagnosis, had a shorter disease duration and higher SLEDAI and PGA scores. This group of patients also presented greater impact in all LupusQoL domains (Table 2) and in the WPAI (Table 3). Moreover, the MV analysis for Question 6 of the WPAI demonstrate a significant higher degree health regular activities impairment and active LN after adjusting for confounders (p=0.02) (Data not shown).

Conclusion: In this cohort, we have shown that active LN significantly affects the patients’ QoL especially in their physical health, emotional health, body image and fatigue. In addition, an impact in work productivity and activity impairment was observed in this group.

PGA: Physician Global Assessment. SLEDAI_2k: Systemic Lupus Erythematosus Disease Activity Index. SDI: damage with the SLICC/ACR Damage Index. Immunosuppressors1: Mycophenolate, Methotrexate, Azathioprine, Oral Cyclophosphamide, Intravenous Cyclophosphamide, Tacrolimus, Ciclosporin A.

Lupus QoL questions within each domain were categorized as: never or present at different degree Percentages reflect positive responses (i.e., present) on the QOL questions

*Questions 5 and 6 measures a scale from 0 to 10 being 10 the highest involvement

Disclosures: R. Nieto, None; E. Ferreira Borba, None; E. Settecasse, None; D. Fernandez-Avila, None; L. Maurelli, None; C. Gobbi, None; V. Saurit, None; F. Arizpe, None; J. Daniele, None; M. Bertolaccini, None; E. Kerzberg, None; M. Gargiulo, None; A. Rodriguez, None; A. Londe, None; V. Barbosa, None; A. Gasparin, None; C. Albanez A Cunha Andrade, None; L. Parente Costa Seguro, None; L. Victoria de Oliveira Martins, None; O. Neira, None; C. Llanos, None; L. Massardo, None; A. Iglesias, None; I. Nieto Aristizábal, None; G. Vasquez, None; P. Mendez-Patarroyo, None; L. Rueda, None; J. Martínez Pérez, None; R. Sánchez Briones, None; M. Pérez Cristóbal, None; E. Martin-Nares, None; Y. Juárez-Vicuña, None; Y. Gonzalez Bello, None; J. González García, None; D. Galarza-Delgado, None; M. Vázquez, None; P. Langjarh, None; M. Alva Linares, None; C. Reategui-Sokolova, Jannsen, 5; A. Calvo Quirós, None; E. Rodriguez, None; R. Robaina, Roche, 12, participation in congresses; M. Rebella, Abbvie, 6, 12, participation in congresses, pfizer, 12, participation in congresses, Roche, 12, participation in congresses; G. Alarcn, None; A. Orillion, None; C. Karyekar, Janssen Global Services, LLC, 3, 11; F. Zazzetti, Janssen, 3; G. Pons-Estel, GSK, 1, 6, Pfizer, 1, 6, Janssen, 6, Janssen, 5, Sanofi, 1.

To cite this abstract in AMA style:

Nieto R, Ferreira Borba E, Settecasse E, Fernandez-Avila D, Maurelli L, Gobbi C, Saurit V, Arizpe F, Daniele J, Bertolaccini M, Kerzberg E, Gargiulo M, Rodriguez A, Londe A, Barbosa V, Gasparin A, Albanez A Cunha Andrade C, Parente Costa Seguro L, Victoria de Oliveira Martins L, Neira O, Llanos C, Massardo L, Iglesias A, Nieto Aristizábal I, Vasquez G, Mendez-Patarroyo P, Rueda L, Martínez Pérez J, Sánchez Briones R, Pérez Cristóbal M, Martin-Nares E, Juárez-Vicuña Y, Gonzalez Bello Y, González García J, Galarza-Delgado D, Vázquez M, Langjarh P, Alva Linares M, Reategui-Sokolova C, Calvo Quirós A, Rodriguez E, Robaina R, Rebella M, Alarcn G, Orillion A, Karyekar C, Zazzetti F, Pons-Estel G. Impact of Active Lupus Nephritis in Patient-Reported Outcomes from a Latin American, Multicenter Lupus Cohort [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/impact-of-active-lupus-nephritis-in-patient-reported-outcomes-from-a-latin-american-multicenter-lupus-cohort/. Accessed .

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/impact-of-active-lupus-nephritis-in-patient-reported-outcomes-from-a-latin-american-multicenter-lupus-cohort/